Cutanea Life Sciences has announced the availability of Aktipak (erythromycin and benzoyl peroxide) Gel, 3%/5% for the topical treatment of acne vulgaris.
Aktipak is a portable, patient-blended therapy that comes in a pocket-sized, single-dose, dual-chamber pouch, each of which contain the antibiotic erythromycin and the antibacterial benzoyl peroxide in separate chambers. The patient opens the pouch and mixes the gel contents (in the palm of the hand) immediately prior to each use.
A multicenter, randomized, double-blind parallel group study of the efficacy of Aktipak versus vehicle was conducted in 217 acne patients 13 years of age and older. At 8 weeks, treatment success, as defined by the Physician’s Global Acne Severity score, was demonstrated in 36% for the Aktipak group versus 12% for the vehicle group (p <0.05). The most frequently reported side effects included dry skin (7.6%), application site reaction (2.5%), blepharitis (1.7%), pruritus (1.7%) and photosensitivity (1.3%).
Aktipak will be available this April in cartons containing 60 pouches. The product has an 18-month shelf life from the date of manufacture, and no refrigeration is required.
For more information visit Aktipak.com.